1. Home
  2. DUOT vs ALXO Comparison

DUOT vs ALXO Comparison

Compare DUOT & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DUOT

Duos Technologies Group Inc.

HOLD

Current Price

$13.77

Market Cap

244.3M

Sector

Technology

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.80

Market Cap

240.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DUOT
ALXO
Founded
1990
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
244.3M
240.8M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
DUOT
ALXO
Price
$13.77
$1.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$17.00
$3.50
AVG Volume (30 Days)
828.9K
933.6K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
53.96
26.36
EPS
N/A
N/A
Revenue
$27,023,651.00
N/A
Revenue This Year
$50.98
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
271.16
N/A
52 Week Low
$5.78
$0.41
52 Week High
$15.28
$2.66

Technical Indicators

Market Signals
Indicator
DUOT
ALXO
Relative Strength Index (RSI) 68.08 41.81
Support Level $8.12 $1.54
Resistance Level N/A $1.90
Average True Range (ATR) 1.22 0.11
MACD 0.44 -0.03
Stochastic Oscillator 80.36 25.61

Price Performance

Historical Comparison
DUOT
ALXO

About DUOT Duos Technologies Group Inc.

Duos Technologies Group Inc delivers AI-driven technologies, edge computing infrastructure, and energy consulting services to support data-intensive and mission-critical operations. It manages, operates, engineers, software development, customer support and project implementation and management across three market segments, including rail technology deployment, Data Center co-location facilities, and behind-the-meter electrical power provision. It also continues to operate as a technology company which designs, develops, deploys, and operates intelligent technology solutions with a focus on software applications and artificial intelligence (AI) in addition to large projects, consulting, implementation, and asset management.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: